Rebecca Klisovic, MD

Current OSU Appointments

Assistant Professor-Clinical, Hematology

Physician, FGP-Hematology

Clinical Services

09/01/2005	Outpatient Clinic (Hematology)
07/01/2007	BMT Service (James Cancer Hospital, Hematology)
10/01/2007	Hem II Service (James Cancer Hospital, Hematology)
12/01/2007	BMT Service (James Cancer Hospital, Hematology)
12/01/2007	BMT Service (James Cancer Hospital, Hematology)
01/01/2008	BMT Service (James Cancer Hospital, Hematology)
03/01/2008	BMT Service (James Cancer Hospital, Hematology)
04/01/2008	BMT Service (James Cancer Hospital, Hematology)
05/01/2008	BMT Service (James Cancer Hospital, Hematology)
06/01/2008	Hem II Service (James Cancer Hospital, Hematology)
07/01/2008	Hem II Service (James Cancer Hospital, Hematology)
08/01/2008	Hem II Service (James Cancer Hospital, Hematololgy)
09/01/2008	HNP Service (James Cancer Hospital, Hematology)
10/01/2008	Hem II Service (James Cancer Hospital, Hematology)
11/01/2008	BMT Service (James Cancer Hospital, Hematology)
12/01/2009	HEM II In Patient Service (James Cancer Hospital, Hematology/Oncology)
01/01/2010	HEM II In Patient Service (James Cancer Hospital, Hematology/Oncology)
03/01/2010	HEM II In Patient Service (James Cancer Hospital, Hematology/Oncology)
04/01/2010	HEM II In Patient Service (James Cancer Hospital, Hematology)
05/01/2010	Hematology II Inpatient Service
06/01/2010	Hematology II Inpatient Service
07/01/2010	Hematology II Inpatient Service
08/01/2010	Hematology II Inpatient Service
08/01/2010	Hematology II Inpatient Service
08/01/2010	Hematology II Inpatient Service
10/01/2010	Hematology II Inpatient Service
11/01/2010	Hematology II Inpatient (James Cancer Hospital)
12/01/2010	Blood and Marrow Transplantation Inpatient Service (James Cancer Hospital)
02/01/2011	Hematology II Inpatient Service (James Cancer Hospital)
05/01/2011	Blood and Marrow Transplantation Inpatient Service (James Cancer Hospital)
10/01/2011	Hematology II Inpatient Service (James Cancer Hospital)

Journal Articles

Marcucci, Guido; Bruner, Rebecca J.; Binkley, Philip F.; Xiao, Jim; Chan, Kenneth K.; Parthun, Mark; Davis, Melanie; Fischer, Beth; Shank, Roshini; Moran, Mollie; Byrd, John C.; Grever, Michael. "Phase I Trial of the Histone Deacetylase Inhibitor Depsipeptide (FR901228) in Acute Myeloid Leukemia (AML).." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 317-.

Shea, Thomas, C; Bruner, Rebecca; Wiley, Joseph, M; Serody, Jonathan, S; Sailer, Scott; Gabriel, Don, A; Capel, Eileen; Moore, Dominic, T; Dent, Georgette; Bentley, Stuart; Brecher, Mark E. "An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies.." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Vol. 9, no. 7. (January 2003.): 443-52.

Griffin, John H.; Leung, Joey; Bruner, Rebecca J.; Caligiuri, Michael A.; Briesewitz, Roger. "Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.." Proceedings of the National Academy of Sciences of the United States of America. Vol. 100, no. 13. (January 2003.): 7830-7835.

De Angelo, Daniel J.; Stone, Richard M.; Bruner, Rebecca J.; Caligiuri, Michael A.; Heaney, Mark L.; Nimer, Stephen D.; Paquette, Ronald; Sawyers, Charles L.; Lambing, Joe L.; Lokker, Nathalie A.; Giese, Neill A.; Sinha, Vikram; Cooper, Michael R.; Druker, Brian J.; Heinrich, Michael C.. "Phase I clinical results with MLN518, a novel FLT3 antagonist: Tolerability, pharmacokinetics, and pharmacodynamics.." Blood. Vol. 102, no. 11. (January 2003.): 65a-66a.

Bruner, Rebecca J ; Farag, Sherif S.. Monoclonal antibodies for the prevention and treatment of graft-versus-host disease. Vol. 30, no. 4. (January 2003.): 509-519.

Marcucci,G; Stock,W; Dai,G; Liu,S; Klisovic,R; Klisovic,M,I; Sher,D; Huynh,L; FRANKEL,S; Blum,W; Larson,R,A; Grever,M,R; Byrd,J,C; Chan,K,K. "Intracellular levels of oblimersen sodium and target downregulation correlates to clinical activity of bcl-2 antisense in acute myeoid leukemia (AML).." BLOOD. Vol. 104, no. 11. (November 2004.): 331A-331A.

Marcucci,G; Stock,W; Dai,G; Klisovic,M,I; Maharry,K; Shen,T; Liu,S; Sher,D,A; Lucas,D; ZWIEBEL,A; Larson,R,A; Caligiuri,M,A; Bloomfield,C,D; Chan,K,K; Grever,M,R; Byrd,J,C. "G3139, a BCL-2 antisense oligo-nucleotide, in AML.." Annals of hematology. Vol. 83, (January 2004.): S93-4.

Whitman,S,P; Liu,S,J; Vukosavljevic,T; Rush,L,J; Yu,L; Liu,C,H; Klisovic,M,I; Maharry,K; Guimond,M; Strout,M,P; Becknell,B; Dorrance,A; Klisovic,R,B; Plass,C; Bloomfield,C,D; Marcucci,G; Caligiuri,M,A. "The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy." BLOOD. Vol. 106, no. 1. (July 2005.): 345-352.

Byrd, John, C; Marcucci, Guido; Parthun, Mark, R; Xiao, Jim, J; Klisovic, Rebecca, B; Moran, Mollie; Lin, Thomas, S; Liu, Shujun; Sklenar, Amy, R; Davis, Melanie, E; Lucas, David, M; Fischer, Beth; Shank, Roshini; Tejaswi, Sooraj, L; Binkley, Philip; Wright, John; Chan, Kenneth, K; Grever, Michael R. "A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.." Blood. Vol. 105, no. 3. (January 2005.): 959-67.

Byrd,J,C; Marcucci,G; Parthun,M,R; Xiao,J,J; Klisovic,R,B; Moran,M; Lin,T,S; Liu,S,J; Sklenar,A,R; Davis,M,E; Lucas,D,M; Fischer,B; Shank,R; Tejaswi,S,L; Binkley,P; Wright,J; Chan,K,K; Grever,M,R. "A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia." BLOOD. Vol. 105, no. 3. (February 2005.): 959-967.

Neviani,P; Santhanam,R; Trotta,R; Notari,M; Blaser,B,W; Liu,S,J; Mao,H; Chang,J,S; Galietta,A; Uttam,A; Roy,D,C; Valtieri,M; Bruner-Klisovic,R; Caligiuri,M,A; Bloomfield,C,D; Marcucci,G; Perrotti,D. "The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein." CANCER CELL. Vol. 8, no. 5. (November 2005.): 355-368.

Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novic S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, and Byrd JC. "Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity." J Clin Oncol. Vol. 23, no. 15. (January 2005.): 1-7.

Whitman, Susan, P; Liu, Shujun; Vukosavljevic, Tamara; Rush, Laura, J; Yu, Li; Liu, Chunhui; Klisovic, Marko, I; Maharry, Kati; Guimond, Martin; Strout, Matthew, P; Becknell, Brian; Dorrance, Adrienne; Klisovic, Rebecca, B; Plass, Christoph; Bloomfield, Clara, D; Marcucci, Guido; Caligiuri, Michael A. "The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy.." Blood. Vol. 106, no. 1. (January 2005.): 345-52.

Liu,Shujun; Pang,Jiuxia; Yu,Jianhua; Liu,Zhongfa; Huynh,LeNguyen; Kearney,Jessica; Paschka,Peter; Klisovic,Rebecca,B; Baiocchi,Robert; Blum,William; Perrotti,Danilo; Marcucci,Guido. "Bortezomib-induced down-regulation of KIT is mediated by inhibition of Sp1 and NF-kB in AML1/ETO-positive cells.." BLOOD. Vol. 108, no. 11. (November 2006.): 132B-132B.

DeAngelo,Daniel,J; Amrein,Philip,C; Kovacsovics,Tibor,J; Klisovic,Rebecca,B; Powell,Bayard,L; Cooper,Michael; Webb,Iain,J; Stone,Richard,M. "Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML).." BLOOD. Vol. 108, no. 11. (November 2006.): 51A-51A.

Blum,William; Marcucci,Guido; Devine,Hollie; Klisovic,Rebecca. "Imatinib mesylate-induced complete cytogenetic response in acute myeloid leukemia with t(5;12)(q33;p13).." BLOOD. Vol. 108, no. 11. (November 2006.): 181B-181B.

Blum,William; Klisovic,Rebecca,B; Kefauver,Cheryl; Johnson,Amy; Phelps,Mitch; Dalton,James,T; Lucas,David; Huynh,Le,Nguyen; Liu,Shujun; Grever,Michael,R; Colevas,A,D; Marcucci,Guido; Byrd,John,C. "Updated results of a phase I study of flavopiridol in acute leukemias using a novel, pharmacolkinetically derived schedule: Clinical activity including hyperacute tumor lysis syndrome (TLS), pharmacokinetics (PIC), and pharmacodynamics (PD).." BLOOD. Vol. 108, no. 11. (November 2006.): 224B-224B.

Ali,Naeem,A; O'Brien,James,M; Blum,William; Klisovic,Rebecca,B; Marcucci,Guido; Phillips,Gary; Marsh,Clay,B; Lemeshow,Stanley; Byrd,John,C; Grever,Michael,R. "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.." BLOOD. Vol. 108, no. 11. (November 2006.): 476B-476B.

Sun,Jin; Liu,Shujun; Yu,Jianhua; Wei,Min; Mao,Charlene; Ding,Haiming; Kearney,Jessica; Huynh,LeNguyen; Paschka,Peter; Wang,Dachun; Klisovic,Rebecca,B; Perrotti,Danilo; Chen,Ching-Shih; Blum,Williom,George; Marcucci,Guido. "Characterization of HDACI OSU42 as a novel histone deacetylase inhibitor in AML cell lines.." BLOOD. Vol. 108, no. 11. (November 2006.): 563A-563A.

DeAngelo,Daniel,J; Stone,Richard,M; Heaney,Mark,L; Nimer,Stephen,D; Paquette,Ronald,L; Klisovic,Rebecca,B; Caligiuri,Michael,A; Cooper,Michael,R; Lecerf,Jean-Michel; Karol,Michael,D; Sheng,Shihong; Holford,Nick; T Curtin,Peter; Druker,Brian,J; Heinrich,Michael,C. "Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics." BLOOD. Vol. 108, no. 12. (December 2006.): 3674-3681.

Cheng, Hao; Liu, Zhongfa; Blum, William; Byrd, John, C; Klisovic, Rebecca; Grever, Michael, R; Marcucci, Guido; Chan, Kenneth K. "Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS.." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. Vol. 850, no. 1-2. (January 2007.): 206-212.

Blum,William; Klisovic,Rebecca,B; Johnson,Amy; Kefauver,Cheryl; Phelps,Mitch; Lucas,David; Huynh,LeNguyen; Liu,Shujun; Dalton,James,T; Grever,Michael,R; Marcucci,Guido; Byrd,John,C. "Final results of a dose escalation study of flavopiridol in acute leukemias using a novel-treatment schedule." BLOOD. Vol. 110, no. 11. (November 2007.): 272A-272A.

Hamadani,Mehdi; Elder,Patrick; Awan,Farrukh; Krugh,David; Blum,William; Lin,Thomas; Andritsos,Leslie; Bechtel,Thomas; Blum,Kristie; Klisovic,Rebecca; Devine,Steven,M. "High rates of early donor chimerism and low risk of chronic GVHD can be achieved in poor risk patients undergoing unrelated donor stem cell transplantation using a reduced intensity conditioning regimen incorporating fludarabine, busulfan, and rabbit ATG." BLOOD. Vol. 110, no. 11. (November 2007.): 351B-351B.

Blum W, Klisovic RB , Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G. "Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia." J Clin Oncol. Vol. 25, no. 25. (January 2007.): 3884-3891.

Ali NA, O’Brien JM, Blum W, Byrd JC, Klisovic RB, Marcucci G, Phillips G, Marsh CB, Lemeshow S, Grever MR. "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality." Cancer. Vol. 110, no. 1. (January 2007.): 96-102.

Liu S, Klisovic RB , Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Liu Z, Neviani P, Blum W, Chan KK, Perrotti D, and Marcucci G. "Targeting AML1/ETO-HDAC repressor complex: a novel mechanism for valproic acid mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells." J Pharmacol Exp Ther. Vol. 321, no. 3. (January 2007.): 953-960.

Klisovic,Rebecca,B; Coutre,Steven; Kovacsovics,Tibor,J; Kantarjiam,Hagop,M; Tricot,Guido,J; Strovel,Jeffrey,W; Genna,Thomas; Bol,David,K; Hamilton,Michael; Mitchell,Beverly,S. "Clinical-biomarker correlations in adult AML patients in a phase I trial of AVN944 support observations of clinical effect and provide hypotheses for patient selection criteria for further clinical trials." BLOOD. Vol. 110, no. 11. (November 2007.): 273A-274A.

Liu, Zhongfa; Liu, Shujun; Xie, Zhiliang; Blum, William; Perrotti, Danilo; Paschka, Peter; Klisovic, Rebecca; Byrd, John; Chan, Kenneth, K; Marcucci, Guido. "Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.." Nucleic acids research. Vol. 35, no. 5. (January 2007.): -.

Blum,William; Klisovic,Rebecca; Liu,Shujun; Garzon,Ramiro; Kefauver,Cheryl; Liu,Zhongfa; Mickle,Jon; Devine,Hollie; Devine,Steve; Grever,Michael,R; Chan,Kenneth,K; Villalona-Calero,Miguel; Byrd,John,C; Marcucci,Guido. "Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age >= 60) with Previously Untreated Acute Myeloid Leukemia (AML)." BLOOD. Vol. 112, no. 11. (November 2008.): 1016-1016.

Wei X, Dai G, Liu Z, Cheng H, Xie Z, Klisovic R, Marcucci G, Chan K. "Enzyme kinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleatide reductase.." http://dmd.aspetjournals.org. Vol. 36, no. 11. (January 2008.): 2227-2233.

Klisovic RB , Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan KK, Marcucci G. "Phase I study of GTI-2040, an anti-sense to ribonucleotide reductase, in combination with high dose cytarabine in patients with acute myeloid leukemia." Clin Cancer Res. Vol. 14, no. 12. (January 2008.): 3889-3895.

Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G. "A Phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase I, in patients with high-risk myelodysplasia and acute myeloid leukemia." Clinical Cancer Research. no. 14(8): 2444-9. (January 2008.): -.

Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehman E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caliguiri MA, Chan KK, Wu LC, Marcucci G. "Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methytransferase activity in acute myeloid leukemia.." Blood. Vol. 11, no. 4. (January 2008.): 2364-73.

Klisovic,Rebecca,B; Stock,Wendy; Cataland,Spero; Klisovic,Marko,I; Liu,Shujun; Bium,William; Green,Margaret; Odenike,Olatoyosi; Godley,Lucy; Burgt,Jennifer,Vanden; Van Laar,Emily; Cullen,Michael; MacLeod,A,Robert; Besterman,Jeffrey,M; Reid,Gregory,K; Byrd,John,C; Marcuccil,Guido. "A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia." CLINICAL CANCER RESEARCH. Vol. 14, no. 8. (April 2008.): 2444-2449.

Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Elder P, Blum K, Penza S, Lin TS, Klisovic RB, Marcucci G, Farag SS, Devine SM. "Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogenic peripheral blood cell transplantation.." Biol Blood Marrow Transplant. Vol. 14, no. 7. (January 2008.): 783-9.

Hamadani M; Blum W; Phillips G; Elder P; Andritsos L; Hofmeister C; O'Donnell L; Klisovic R; Penza S; Garzon R; Krugh D; Lin T; Bechtel T; Benson DM; Byrd JC; Marcucci G; Devine SM. "Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.." Biology Of Blood And Marrow Transplantation: Journal Of The American Society For Blood And Marrow Transplantation. Vol. 15, no. 11. (November 2009.): 1422-.

Chen P, Liu Z, Liu S, Xie Z, Aimiuwu J, Pang J, Klisovic R , Blum W, Grever MR, Marcucci G, Chan KK. "A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels." Pharm Res. Vol. 26, no. 6. (March 2009.): 1504-1515.

Chen,Ping; Blum,William; Aimiuwu,Josephine; Upadhyayula,Vijayasarathi; Liu,Zhongfa; Liu,Shujun; Pang,Jiuxia; Walker,Alison; Klisovic,Rebecca,B; Garzon,Ramiro; Grever,Michael,R; Villalona-Calero,Miguel; Byrd,John,C; Chan,Kenneth,K; Marcucci,Guido. "Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine." BLOOD. Vol. 114, no. 22. (November 2009.): 1454-1455.

Chandler,Jason,C; Klisovic,Rebecca,B; Phelps,Mitch,A; Walker,Alison; Garzon,Ramiro; Yang,Xiaoxia; Schaaf,Larry; Schwind,Sebastian; Becker,Heiko; Liu,Shujun; Hickey,Chris; Kefauver,Cheryl; Mickle,Jon; Devine,Steven,M; Grever,Michael,R; Byrd,John,C; Marcucci,Guido; Blum,William. "Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia." BLOOD. Vol. 114, no. 22. (November 2009.): 346-347.

Blum,William; Klisovic,Rebecca,B; Walker,Alison; Garzon,Ramiro; Liu,Shujun; Schaaf,Larry,J; Humphries,Kristina; Grever,Michael,R; Devine,Steven,M; Byrd,John,C; Marcucci,Guido. "Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML)." BLOOD. Vol. 114, no. 22. (November 2009.): 815-816.

W. Blum, MA Phelps, RB Klisovic, DM Rozewski, W Ni, KA Albanese, B Rovin, C Kefauver, SM Devine, DM Lucas, A Johnson, LJ Schaaf, JC Byrd, G Marcucci, MR Grever. "Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.." Haematologica. Vol. 95, no. 7. (May 2010.): 1098-1105.

Blum,William; Klisovic,Rebecca,B; Garzon,Ramiro; Walker,Alison; Schwind,Sebastian; Liu,Shujun; Schaaf,Larry; Garr,Celia; Devine,Steven,M; Greyer,Michael,R; Byrd,John,C; Marcucci,Guido. "Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)." BLOOD. Vol. 116, no. 21. (November 2010.): 1349-1349.

Blum W; Garzon R; Klisovic RB; Schwind S; Walker A; Geyer S; Liu S; Havelange V; Becker H; Schaaf L; Mickle J; Devine H; Kefauver C; Devine SM; Chan KK; Heerema NA; Bloomfield CD; Grever MR; Byrd JC; Villalona-Calero M; Croce CM; Marcucci G. "Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.." Proceedings Of The National Academy Of Sciences Of The United States Of America. Vol. 107, no. 16. (April 2010.): 7473-.

Blum W, Klisovic RB , Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC. "Dose escalation of lenalidomide in relapsed or refractory acute leukemias." J Clin Onc. Vol. 28, no. 33. (November 2010.): 4919-4925.

Chen P, Aimiuwu J, Xie Z, Wei X, Liu S, Klisovic R , Marcucci G, Chan KK. "Biochemical modulation of Aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 leukemia cells." AAPS. Vol. 13, no. 1. (March 2011.): 131-140.

Rondelli,Damian; Goldberg,Judith,D; Marchioli,Roberto; Isola,Luis; Shore,Tsiporah,B; Prchal,Josef,T; Bacigalupo,Andrea; Rambaldi,Alessandro; Klisovic,Rebecca,B; Gupta,Vikas; Andreasson,Bjorn; Demakos,Erin,P; Price,Leah,S; Scarano,Marco; Wetzler,Meir; Vannucchi,Alessandro,M; Najfeld,Vesna; Barosi,Giovanni; Silverman,Lewis,R; Hoffman,Ronald. "Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis." BLOOD. Vol. 118, no. 21. (November 2011.): 763-763.

KH Metzeler, A Walker, S Geyer, R Garzon, RB Klisovic , CD Bloomfield, W Blum, and G Marcucci. "DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia." Leukemia. Vol. 26, no. 5. (January 2011.): 1106-1107.

Walker,Alison,R; Metzeler,Klaus,H; Geyer,Susan; Becker,Heiko; Schwind,Sebastian; Whitman,Susan,P; Curfman,John; Wu,Yue-Zhong; Perrotti,Danilo; Klisovic,Rebecca,B; Garzon,Ramiro; Blum,William; Marcucci,Guido. "Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute-Myeloid Leukemia (AML)." BLOOD. Vol. 118, no. 21. (November 2011.): 430-430.

Blum,William; Schwind,Sebastian; Tarighat,Somayeh,S; Geyer,Susan; Eisfeld,Ann-Kathrin; Whitman,Susan; Walker,Alison; Klisovic,Rebecca; Byrd,John,C; Santhanam,Ramasamy; Wang,Hongyan; Curfman,John,P; Devine,Steven,M; Jacob,Samson; Garr,Celia; Kefauver,Cheryl; Perrotti,Danilo; Chan,Kenneth,K; Bloomfield,Clara,D; Caligiuri,Michael,A; Grever,Michael,R; Garzon,Ramiro; Marcucci,Guido. "Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia." BLOOD. Vol. 119, no. 25. (June 2012.): 6025-6031.

Ranganathan,Parvathi; Yu,Xueyan; Na,Caroline; Santhanam,Ramasamy; Shacham,Sharon; Kauffman,Michael; Walker,Alison; Klisovic,Rebecca; Blum,William; Caligiuri,Michael; Croce,Carlo,M; Marcucci,Guido; Garzon,Ramiro. "Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.." Blood. Vol. 120, no. 9. (August 2012.): 1765-1773.

Pearlly Yan, David Frankhouser, Mark Murphy, Hok-Hei Tam, Benjamin Rodriguez, John Curfman, Michael Trimarchi, Susan Geyer, Yue-Zhong Wu, Susan P. Whitman, Klaus Metzeler, Alison Walker, Rebecca Klisovic, Samson Jacob, Michael R. Grever, John C. Byrd, Clara D. Bloomfield, Ramiro Garzon, William Blum, Michael A. Caligiuri, Ralf Bundschuh, Guido Marcucci.. "Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.." Blood.. Vol. 10, (July 2012.): 1182-.

Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, Lee LJ, Jacob S, Mrozek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci G.. "Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting approach in acute myeloid leukemia.." Leukemia. Vol. doi: 10.1038, (November 2012.): leu.2012.342-.

Aimiuwu,Josephine; Wang,Hongyan; Chen,Ping; Xie,Zhiliang; Wang,Jiang; Liu,Shujun; Klisovic,Rebecca; Mims,Alice; Blum,William; Marcucci,Guido; Chan,Kenneth,K. "RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.." Blood. Vol. 119, no. 22. (May 2012.): 5229-5238.

Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci G.. "In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia." AAPS J. Vol. Doi: 10.1208/S12248-012-9427-5, (November 2012.): 1-8.

Reference Works

January 1992	Panigutti MA, Merritt K, Bruner RJ, Kraay MJ, Brown SA."Correlation of allergy metal levels, implant alloy, and implant damage in patients undergoing revision joint anthroplasty." .
January 1992	Bruner RJ, Merritt K, Brown SA, Panigutti MA."Incidence of allergy in patients undergoing total joint revision." .
January 1993	Bruner RJ, Merritt K, Brown SA, Kraay MJ."Metal sensitivity in patients undergoing total joint revision." .
January 1995	Shoemaker LH, Bruner RJ, Fristad M, Cromer B."Primary health care problems in adolescents with psychiatric disorders." .
January 2000	Gabriel DA, Shea T, Wiley J, Serody J, Kirby S, Bruner RJ, Capel E, Bigelow S, Morris D, Banderencko N, Brecher M."Use of amifostine to reduce mucositis following total brain irradiation-based autotransplants for lymphoma." .
January 2002	Sooraj LN, Marcucci G, Byrd JC, Bruner RJ, Fischer B, Hatton P, Grever M, Binkley PF."Cardiovascular response to depsipeptide: Absense of cardiotoxicity in human recipients." .
January 2002	Marcucci G, Bruner RJ, Binkley PF, Xia J, Chan KK, Parthun M, Davis M, Fischer B, Shank R, Mroan M, Byrd JC, Grever M."Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228) in acute myeloid leukemia." .
January 2002	Whitman SP, Guimond M, Blaser B, Klisovic M, Vukosavlijevic T, Bruner RJ, Ruppert AS, Becknell B, Barbosa X, Griffen J, Briesewitz R, Caliguiri."Primary acute myeloid leukemia cells with the FLT3 internal tandem duplication (ITD) and absence of wild-type (WT) FLT3 (FLT3 Genotype) are distinct from AML with either FLT3 or FLT3 genotypes." .
January 2002	De Angelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette R, Klisovic RB, Caligiuri MA, Cooper MR, LeCerf J-M, Lyer G, Heinrich MC, Druker BJ."Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with Acute Myeloid Leukemia (AML)" .
January 2002	Bruner RJ, Marcucci G, Binkley P, Xiao J, Chan K, Parthun M, Davis M, Fischer B, Shank R, Moran M, Grever M, Byrd JC."Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228) in fludarabine refactory chronic lymphocytic leukemia." .
January 2002	Bruner RJ, Marcucci G, Binkley P, Xiao J, Chan K, Parthun M, Davis M, Fischer B, Shank R, Maran M, Grever M, Byrd JC."Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228) in Fludarabine Refactory Chronic Lymphocytic Leukemia" .
January 2002	Bruner RJ, Marcucci G, Binkley P, Fischer B, Parthun M, Davis M, Xiao J, Chan K, Wright J, Grever M, Byrd JC."A phase I study to determine minimally effective pharmacologic dose (MEPD) of depsipeptide (FR901228) in selected hematologic malignancies." .
January 2003	Whitman SP, Liu S, Klisovic MI, Vukosavljevic T, Guimond M, Rush LJ, Ruppert AJ, Strout MP, Becknell B, Dorrance AM, Bruner RJ, Plass C, Bloomfield CD, Marcucci G, Caliguiri M."Activation of the silenced MLL (ALL-1) wild-type allele in Acute Myeloid Leukemia (AML) with the MLL partial tandem duplication results in enhancement of cell death." .
January 2003	De Angelo DJ, Stone RM, Bruner RJ, Caliguiri MA, Heaney ML, Nimer SD, Paquette R, Sawyers CL, Lambing JL, Lokker NA, Giese NA, Sinha V, Cooper MR, Druker BJ, Heinrich MC."Phase I clinical results with MLN518, a novel FLT3 antagonist: tolerability, pharmacokinetics, and pharmacodynamics." .
January 2004	Marcucci G, Stock W, Dai G, Liu S, Klisovic RB, Klisovic MI, Sher D, Huynh L, Frankel S, Blum W, Larson RA, Grever M, Byrd JC, Chan KK."Intracellular levels of oblimersen sodium and target downregulation correlates to clinical activity of bcl-2 antisense in Acute Myeloid Leukemia (AML)" .
January 2005	Neviani P, Santhanam R, Trotta R, Notari M, Blaser B, Chang J, Liu S, Mao K, Oaks J, Roy D, Valtieri M, Klisovic RB, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D."Resetting PP2A tumor suppressor activity overcomes BCR/ABL leukemogenic potential in blast crisis CML" .
January 2005	Klisovic RB, Blum W, Wei X, Liu S, Kefauver C, Huynh L, Zwiebel JA, Byrd JC, Grever M, Marcucci G."A phase I study of GTI-2040, and antisense to Ribonucleotide Reductase (RNR) in combination with High-Dose Cytarabine (HiDAC) in relapsed or refactory Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and clinical results." .
January 2005	Blum W, Klisovic RB, Liu S, Byrd JC, Liu Z, Chan KK, Kefauver C, Huynh L, Grever MR, Marcucci G."Phase I study of low dose decitabine in patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and clinical activity." .
January 2006	Klisovic RB, Blum W, Hackanson B, Kefauver C, Liu s, Liu Z, Chan K, Plass C, Grever M, Byrd JC, Marcucci G."Updated results of a phase I study of low dose decitabine and valporic acid (VA) in patients with acute myeloid leukemia (AML): Gene reexpression, demethylation and clinical response." .
November 2006	Liu S, Pang J, Yu J, Liu Z, Huynh L, Paschka P, Klisovic RB, Baiocchi R, Blum W, Perrotti D, Marcucci G."Bortezomib-induced down-regulation of KIT is mediated by inhibition of Sp1 and KF-kB in AML1/ETO-postive cells" .
January 2006	Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, Dalton JT, Lucas D, Colevas AD, Grever M, Marcucci G, Byrd JC."Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, phamacokinetics, and pharmacodynamics." .
November 2006	Sun J, Liu S, Yu J, Wei M, Moa C, Ding H, Kearney J, Huynh L, Paschka P, Wang D, Klisovic Rb, Perrotti D, Chen C, Blum W, Marcucci G."Characterization of HDACI OSU42 as a Novel Histone Deacetylas Inhibitor in AML cell lines." .
January 2006	Marcucci G, Klisovic RB, Wei E, Liu S, Liu Z, Chan K, Plass C, Grever MR, Chan K, Blum W."A phase I study of GTI-2040 (6), an antisense to ribonucleotide reductase (RNR), in combination with high-dose AraC (HiDAC) in acute myeloid leukemia (AML)" .
November 2006	DeAngelo D, Amrein P, Kovacsovics T, Klisovic RB, Powell B, Cooper M, Webb I, Stone R.."Phase 1/2 study of Tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML)." .
November 2006	Blum W, Marcucci G, Devine H, Klisovic RB.."Imatinib Mesylate-Induced complete cytogenetic response in AML Myeloid Leukemia with t(5;12)(q33;p13)" .
November 2006	Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, Dalton J, Lucas D, Huynh L, Liu S, Grever M, Colevas A, Marcucci G, Byrd J.."Updated results of a phase I study of Flavopiridol in acute leukemias using a novel, pharmacokinetically derived scheduled clinical activity including hyperacute Tumor Lysis Syndrome (TLS) Pharmacokinetics (PK), and Phamacodynamics (PD)" .
November 2006	Ali N, O'Brien J, Blum W, Klisovic RB, Marcucci G, Phillips G, Marsh C, Lemeshow S, Byrd J, Grever M."Hyperglycemia in patients with acute myeloid leukemia is associated with increrased hospital mortality" .
November 2007	Klisovic RB, Coutre S, Kovacsovics T, Kantarjiam H, Tricot G, Strovel J, Genna T, Krugh D, Hamilton M, Mithcell B."Clinical - Biomarker correlations in adult AML patients in a phase I trial of AVN944 support observations of clinical effect and proven hypotheses for patient selection criteria for further clinical trials" .
November 2007	Hamadani M, Elder P, Awan F, Krugh D, Blum W, Lin T, Andritsos L, Bechtel T, Blum K, Klisovic RB, Devine S.."High rates of early donor chimerism and low risk of chronic GV van be achieved in poor risk patients undergoing unrelated do stem cell transplantation using reduced intensity conditioning regimen incorporating Fludarabine, Busulfan, and Rabbit ATG" .
January 2007	Klisovic RB, Tricot G, Coutre S, Kovacsovics T, Genna T, Bol D, Strovel J, Hamilton M, Mitchell B."A phase I trial of AVN944 in patients with advanced hematologic malignancies." .
November 2007	Blum W, Klisovic RB, Johnson A, Kefauver C, Phelps M, Lucas D, Huynh L, Liu S, Dalton J, Grever M, Marcucci G, Byrd J."Final results of a dose escalation study of Flavopiridol in acute leukemias using a novel treatment schedule." .
November 2008	Odenike O, Godwin J, Van Besien K, Huo D, Sher d, Burke P, Smith S, Green M, Melnick J, Wade J, Lester E, Klisovic RB, Baer M, Larson R, Stock W.."Phase II trial of low-dose, subcutaneous decitabine in Myelofibrosis." Washington D.C.
May 2008	Blum W, Andritsos L, Johnson A, Klisovic RB, Kefauver C, Devine S, Marcucci G, Byrd J."Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL); evidence of activity in acute myeloid leukemia (AML) toxicity in CLL starting dose." .
November 2008	Blum W, Klisovic RB, Liu S, Garzon R, Kefauver C, Liu Z, Mickle J, Devine H, Devine S, Grever M, Chan K, Villalona-Calero M, Byrd J, Marcucci G.."Preliminary results of a Phase II study of low dose decitabine as a single agent in older patients (age>60) with previously untreated acute myeloid leukemia (AML)." Washington D.C.
January 2009	Chen P, Blum W, Aimiuwu J, Upadhyayula V, Liu Z, Liu S, Pang J, Walker A, Klisovic RB, Garzon R, Grever MR, Villalona-Calero M, Byrd JC, Chan KK, Marcuccu G."Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine" New Orleans.
January 2009	Chandler JC, Klisovic RB, Phelps MA, Walker A, Garzon R, Yang Xiaoxia, Schaff L, Schwind S, Becker H, Lui S, Hickey C, Kefauver C, Mickle J, Devine SM, Grever MR, Byrd JC, Marcucci G, Blum W."Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myleoid Leukemia" New Orleans.
May 2009	Blum WG, Klisovic R, Liu S, Kefauver C, Grever MR, Schaaf L, Chan K, Byrd JC, Villalona-Calero M, Marcucci G."Efficacy of a novel schedule of decitabine in previously untreated AML, age 60 or older" .
April 2009	Aimiuwu J, Chen P, Xie Z, Liu Z, Sarathi V, Liu S, Klisovic RB, Marcucci G, Chan K.."In vitro-in vivo pharmacodynamic analisis of GTI-2040 combined with Arc-C acute myeloid leukemia." .
January 2009	Blum W, Klisovic RB, Walker A, Garzon R, Liu S, Schaaf LJ, Humphries K, Grever MR, Devine SM, Byrd JC, Marcucci G."Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia" New Orleans.
November 2010	William Blum, Rebecca B. Klisovic , Ramiro Garzon, Alison Walker, Sebastian Schwind, Shujun Liu, Larry Schaaf, Celia Garr, Steven M. Devine, Michael R. Grever, John C. Byrd, and Guido Marcucci."Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)" Orlando.
November 2010	Klisovic RB , Blum W, Chen P, Xie Z, Liu S, Walker A, Devine S, Garzon R, Byrd J, Wetzler M, Sayar H, Damon L, Grosskretuz C, Colomon S, Murray P, Chan K, Marcucci G."A phase II study of GTI-2040, an antisense to ribonucleotide reductase in combination with high-dose cytarabine in relapsed or refractoy acute myeloid leukemia" .
December 2010	D. Rondelli, M.W. Boyer, L. M. Isola, T. Shore, A. Bacigalupo, R.B. Klisovic, R. Marchiloli, J.D. Goldberg, R. Hoffman, L.R. Silverman,."First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in United States: interim analysis of MPD-RC 101 protocol" Chicago.
January 2011	KH Metzeler, A Walker, S Geyer, R Garzon, RB Klisovic,CD Bloomfield, W Blum and G Marcucci."DNMT3A mutations and response to the hypomethylating agentdecitabine in acute myeloid leukemia" .
January 2011	Alison R. Walker, Klaus H. Metzeler, Susan Geyer, Heiko Becker, Sebastian Schwind, Susan P. Whitman, John Curfman, Yue-Zhong Wu, Danilo Perrotti, Rebecca B. Klisovic , Ramiro Garzon, William Blum, and Guido Marcucci."Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML)" .
January 2011	Damiano Rondelli, Judith D. Goldberg, Roberto Marchioli, Luis Isola, Tsiporah B. Shore, Josef T. Prchal, Andrea Bacigalupo, Alessandro Rambaldi, Rebecca B. Klisovic , Vikas Gupta, Bjorn Andreasson, Erin P. Demakos, Leah S. Price, Marco Scarano, Meir Wetzler, Alessandro M. Vannucchi, Vesna Najfeld, Giovanni Barosi, Lewis R. Silverman, and Ronald Hoffman."Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis" .
February 2012	J. Cooper, D. Krugh, J. Duda, J. Roddy, R. Klisovic, M. Lamprecht, J. Beavers-Kirby, C. Hofmeister, J. Dishon-Ritzert, S. Devine."Improving Vaccination of Patients Pre and Post Bone Marrow Transplant." San Diego.
February 2012	Damiano Rondelli, Judith D. Goldberg, Roberto Marchioli, Luis Isola, Tsiporah B. Shore, Josef T. Prchal, Andrea Bacigalupo, Alessandro Rambaldi, Rebecca B. Klisovic , Vikas Gupta, Bjorn Andreasson, Erin P. Demakos, Leah S. Price, Marco Scarano, Meir Wetzler, Alessandro M. Vannucchi, Vesna Najfeld, Giovanni Barosi, Lewis R. Silverman, and Ronald Hoffman."Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis" San Diego.
March 2012	Schwind S, Samadzadeh S, Geyer S, Klisovic RB, Eisfeld A, Walker A, Whitman S,Ramasamy S, Wu Y, Samson J, caligiuri M, Grever M, Perrotti D, Byrd J, Garzon R, Boomfield C."Cancer Research" Philadelphia.
March 2012	Schwind S, Samadzadeh S, Geyer S, Klisovic RB, Eisfeld A, Walker A, Whitman S,Ramasamy S, Wu Y, Samson J, caligiuri M, Grever M, Perrotti D, Byrd J, Garzon R, Boomfield C."The Combination of Bortezomib (BOR) and Decitabine (DEC): a Phase I Trial in Patients (Pts) with Acute Myeloid Leukemia (AML) targeting FLT3 expression" Chicago.
April 2012	Josephine Aimiuwu, Hongyan Wang, Ping Chen, Zhiliang Xie, Jiang Wang, Shujun Liu, Rebecca Klisovic, Alice Mims, William Blum, Guido Marcucci, Kenneth K. Chan."RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine in acute myeloid leukemia" Washington D.C.
March 2012	Alice S. Mims, Alison R. Walker, Hongyan Wang, Xiaomeng Huang, Ramasamy Santhanam, Pia Hoellerbauer, Somayeh Tarighat, Kenneth K. Chan, Rebecca B. Klisovic, Danilo Perrotti, Michael A. Caligiuri, John C. Byrd, Ching-Shih Chen, William Blum, Ramiro Garzon, Sebastian Schwind, and Guido Marcucci.."AR-42, a Histone Deacetylase Inhibitor, increases microRNA-29b and sensitizes cells to decitabine treatment: a novel epigenetic-targeting approach in Acute Myeloid Leukemia." Philadelphia.
March 2012	Alice S. Mims, Alison R. Walker, Hongyan Wang, Xiaomeng Huang, Ramasamy Santhanam, Pia Hoellerbauer, Somayeh Tarighat, Kenneth K. Chan, Rebecca B. Klisovic, Danilo Perrotti, Michael A. Caligiuri, John C. Byrd, Ching-Shih Chen, William Blum, Ramiro Garzon, Sebastian Schwind, and Guido Marcucci.."AR-42, a Histone Deacetylase Inhibitor, increases microRNA-29b and sensitizes cells to decitabine treatment: a novel epigenetic-targeting approach in Acute Myeloid Leukemia." Chicago.
June 2012	Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce C , Marcucci G, Garzon R.."Pre-clinical activity of a novel CRM1 inhibitor in acute myeloid leukemia." Washington D.C.

Presentations

"Idiopathic Hypereosinophilic Syndrome: Potential new treatment and clues to Pathogenesis." Presented at OSU Medical Center Grand Rounds, . (October 2002)

"A Phase I Study of GT12040 in combination with high-dose Cytarabine in refactory or relapsed AML." Presented at NCI CTEP, . (September 2005)

"Clinical Update on CML." Presented at Chillicothe VA Lecture Series, . (August 2005)

"CML." Presented at Upper Valley Medical Center Grand Rounds, . (October 2009)

"Chronic Myeloid Leukemia and Myeloproliferative Disorders." Presented at OSU ASH Review, . (January 2009)

"Chronic Myeloid Leukemia." Presented at OSU American Society of Cancer Review, Columbus, OH. (January 2011)